【醫療】Farlong Pharmaceutical Completes Three-Year Clinical Trial to Determine Effects of Farlong NotoGinseng™

Just in time for American Heart Health Month, Farlong Pharmaceutical announces the clinical trial results from a randomized, placebo-controlled, double-blind, parallel study on one hundred healthy adults to determine the effect of Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract) on cholesterol and blood pressure, conducted December 2016 through June 2019.

The results showed a significant decrease in serum LDL-C in Farlong NotoGinseng™ group from baseline to week eight. LDL Cholesterol is sometimes called the “bad” cholesterol because a high LDL level leads to a buildup of cholesterol in people’s arteries. There was an increase in serum HDL-C following 12 weeks of supplementation with Farlong NotoGinseng™. HDL (high-density lipoproteins) cholesterol is the “good” cholesterol. There were also within-group decreases in both systolic and diastolic blood pressures.

• 6 Significant areas of Wellness showed a marked improvement with Farlong NotoGinseng™ (Ginseng Plus® Panax Notoginseng extract) compared to placebo. 
• The placebo group had increases in systolic and diastolic blood pressures and had a decrease in serum HDL-C.
• Clinicians suggest that if left unaddressed, these participants may progress to a disease state, and even a small reduction in blood pressure is clinically meaningful in populations at risk for developing cardiovascular diseases.

Find Out More